Hormone therapy in ovarian granulosa cell tumors: A systematic review

Meurs, Hannah S. van; Lonkhuijzen, Luc van; Limpens, Jacqueline; Velden, J. van der; Buist, Marrije R.

doi:10.1016/j.ygyno.2014.03.573

Cited by 91 publications

(87 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent systematic review identified only 19 trials including 31 patients with GCT managed with hormonal agents [32]. However, the pooled objective response rate was 71.0% with a PFS after the start of hormonal therapy of 18 months (range 0-60) [32]. We did not see a similar response rate but did see a prolonged median duration of response of 13.8 months with importantly one patient maintaining a partial response at 4.5 years.…”

Section: Non-surgical Treatment Options At Relapsementioning

confidence: 53%

“…In contrast, the role of hormonal therapy has been popularized with the publication of several case series demonstrating benefit [28][29][30][31]. A recent systematic review identified only 19 trials including 31 patients with GCT managed with hormonal agents [32]. However, the pooled objective response rate was 71.0% with a PFS after the start of hormonal therapy of 18 months (range 0-60) [32].…”

Section: Non-surgical Treatment Options At Relapsementioning

confidence: 99%

See 1 more Smart Citation

Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up

Wilson

Fong

Mesnage

et al. 2015

Gynecologic Oncology

View full text Add to dashboard Cite

Section: Non-surgical Treatment Options At Relapsementioning

confidence: 53%

Section: Non-surgical Treatment Options At Relapsementioning

confidence: 99%

Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up

Wilson

Fong

Mesnage

et al. 2015

Gynecologic Oncology

View full text Add to dashboard Cite

“…Further GCTs express steroid hormone, as well as gonadotropin receptors [6,7] and have been demonstrated to be responsive to pharmacological hormone ablation or receptor blockade in both animal models and humans [1,6,8]. Though endocrine therapies are well tolerated, a recent meta-analysis revealed response rates to be quite heterogeneous [1].…”

Section: Introductionmentioning

confidence: 99%

“…Though endocrine therapies are well tolerated, a recent meta-analysis revealed response rates to be quite heterogeneous [1]. Van Meurs et al [1] hypothesized that various response rates may be caused by different hormone receptor profiles of the respective primary tumor. To this direction, we recently highlighted the G-protein coupled estrogen receptor (GPER/GPR30) to be predictive for epithelial ovarian cancer (EOC) patient survival only in the case of missing co-expression of gonadotropin receptors [9].…”

Section: Introductionmentioning

confidence: 99%

The G-Protein Coupled Estrogen Receptor (GPER/GPR30) in ovarian granulosa cell tumors

Heublein¹,

Ebinger²,

Mayr³

et al. 2014

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

Ovarian granulosa cell tumors (GCTs) are thought to arise from cells of the ovarian follicle and comprise a rare entity of ovarian masses. We recently identified the G-protein-coupled estrogen receptor (GPER/GPR30) to be present in granulosa cells, to be regulated by gonadotropins in epithelial ovarian cancer and to be differentially expressed throughout folliculogenesis. Thus, supposing a possible role of GPER in GCTs, this study aimed to analyze GPER in GCTs. GPER immunoreactivity in GCTs (n = 26; n (primary diagnosis) = 15, n (recurrence) = 11) was studied and correlated with the main clinicopathological variables. Positive GPER staining was identified in 53.8% (14/26) of GCTs and there was no significant relation of GPER with tumor size or lymph node status. Those cases presenting with strong GPER intensity at primary diagnosis showed a significant reduced overall survival (p = 0.002). Due to the fact that GPER is regulated by estrogens, as well as gonadotropins, GPER may also be affected by endocrine therapies applied to GCT patients. Moreover, with our data supposing GPER to be associated with OPEN ACCESSInt. J. Mol. Sci. 2014, 15 15162GCT prognosis, GPER might be considered as a possible confounder when assessing the efficacy of hormone-based therapeutic approaches in GCTs.

show abstract

“…Bone density monitoring is indicated for patients receiving aromatase inhibitors, as is the standard of care in breast cancer treatment. A recent systematic review of hormonal therapy for GrCT reported a pooled response rate of 71% and aromatase inhibitors appear to be the most effective agents, with no reported responses to tamoxifen (52). The role of anastrozole in GrCTs is being assessed in the international multicenter phase II PARAGON trial (ANZGOG 0903), run by the Australia New Zealand Gynaecological Oncology Group.…”

Section: Treatment Surgerymentioning

confidence: 99%